PANGEA LABORATORY
Making Cancer Diagnosis Simple
This proprietary technology proved to be a breakthrough in the development of the multitarget stool DNA test. Our scientists needed to first solve the essential problem of effectively isolating DNA from stool before achieving the goal of developing a noninvasive colon cancer screening test.
The development of an enhanced DNA stabilizing buffer was a critical step in the process of creating a reliable at-home screening kit. With this advance, the DNA in stool samples is protected through the transport process and remains amenable to analysis once it arrives at our processing center.
We developed our proprietary QuARTS technology (Quantitative Allele-specific Real-time Target and Signal Amplification) which efficiently amplifies and quantifies two separate methylated DNA markers (NDRG4 and BMP3) along with seven distinct KRAS gene point mutations. The beta actin (ACTB) gene serves as a reference marker for quantitation of the total amount of human DNA in each sample.
The final step in the multitarget stool DNA test incorporates the quantitative results from the DNA alterations combined with the protein biomarker detection to determine a positive or negative result. This algorithm is the vital workhorse that translates our invisible biology into actionable information.
We improved upon the technology for the ELISA-based detection of a protein biomarker (hemoglobin) through an additive in the stabilization buffer. This innovation allows for longer transit time from sample collection to processing by the lab.
Titulo
The Science of Bladder CARE™
A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study by Ghoreifi A., Seyedian S., Piatti P., et al (2023)
Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples by Piatti P., Chew Y., et al (2021)
Utility of a Urine-Based DNA Methylation Test for Surveillance in Non-Muscle Invasive Bladder Cancer: A Pilot Study by Ladi-Seyedian, S., Ghoreifi, A., et al (2022) – Presented at the American Urological Association General Meeting 2022, and won 3rd place at the Miley B. Wesson Resident Essay Contest t the Western Section American Urological Association 2022
A Urine-Based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Pilot Study by Ghoreifi, A., Ladi-Seyedian, S., et al. (2021) – Presented at the American Urological Association General Meeting 2021 and at the Western Section American Urological Association 2022
Urine Biomarkers for the Detection of Urothelial Carcinoma by Daneshmand, S. (2021) – Presented at Grand Rounds in Urology International Bladder Cancer Update 2021
A Urine-Based DNA Methylation Test to Monitor Response to Neoadjuvant Chemotherapy in Bladder Cancer by Ghodoussipour, S., Basin, M., et al. (2020) – Presented at the American Urological Association General Meeting 2020
Also available in Spanish and Portuguese
Bladder care epigenetic test allows the sensitive early detection of bladder cancer from urine samples by Piatti, P., Suwoto, M., et al. (2020) – Presented at Proceedings of the Annual Meeting of the American Association for Cancer Research 2020
DNA Methylation Cancer Biomarkers: Translation to the Clinic by Locke, W., Guanzon, D., et al. (2019)
Medical Policy: Urinary Tumor Markers for Bladder Cancer
BlueCross BlueShield of North Carolina
BlueCross BlueShield of New Mexico